regadenoson has been researched along with Kidney Failure, Chronic in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (92.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Doukky, R; Iskander, F; Iskander, M; Khan, R; Kolkailah, AA; Patel, PP | 1 |
| Doukky, R; Golzar, Y; Vij, A | 1 |
| Bajaj, NS; Gupta, A | 1 |
| Ananthasubramaniam, K; Bhatti, S; Dhanalakota, S; Hakeem, A; Husain, Z; Jacobsen, G; Palani, G | 1 |
| Bengel, FM; Caobelli, F | 1 |
| Dick, R; Doukky, R; Morales Demori, R; Rangel, MO; Voll, ST; Wassouf, M | 1 |
| Ali, A; AlJaroudi, W; Campagnoli, T; Doukky, R; Fughhi, I; Wassouf, M | 1 |
| Ali, A; Campagnoli, T; Doukky, R; Fughhi, I; Wassouf, M | 1 |
| Miller, EO; Schwartz, RG | 1 |
| Aljaroudi, W; Hage, F; Heo, J; Hermann, D; Iskandrian, AE | 1 |
| Ananthasubramaniam, K; Bukofzer, S; Feaheny, K; Klauke, B; McNutt, B; Weiss, R | 1 |
| Pandit, A; Unzek Freiman, S | 1 |
| Hage, FG; Heo, J; Iskandrian, AE | 1 |
| Alqaid, A; Dick, R; Doukky, R; Morales Demori, R; Rangel, MO; Wassouf, M | 1 |
2 review(s) available for regadenoson and Kidney Failure, Chronic
| Article | Year |
|---|---|
Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.
Topics: Adenosine A2 Receptor Agonists; Aminophylline; Comorbidity; Exercise Test; Humans; Kidney Failure, Chronic; Kidney Function Tests; Myocardial Perfusion Imaging; Observational Studies as Topic; Patient Safety; Prognosis; Purines; Pyrazoles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk; Tomography, Emission-Computed, Single-Photon | 2018 |
The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
Topics: Adenosine A2 Receptor Agonists; Comorbidity; Diarrhea; Dizziness; Drug-Related Side Effects and Adverse Reactions; Exercise Test; Female; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Perfusion Imaging; Pilot Projects; Prospective Studies; Purines; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Tomography, Emission-Computed, Single-Photon; United States; Vasodilator Agents | 2013 |
3 trial(s) available for regadenoson and Kidney Failure, Chronic
| Article | Year |
|---|---|
Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials.
Topics: Adenosine A2 Receptor Agonists; Adult; Aged; Aminophylline; Cardiotonic Agents; Double-Blind Method; Drug Administration Schedule; Exercise Test; Female; Gastrointestinal Tract; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Renal Insufficiency, Chronic | 2015 |
Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease.
Topics: Causality; Comorbidity; Death, Sudden, Cardiac; Double-Blind Method; Exercise Test; Female; Heart Rate; Heart Rate Determination; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Prognosis; Purines; Pyrazoles; Risk Factors; Survival Rate; Tomography, Emission-Computed, Single-Photon; United States; Vasodilator Agents | 2016 |
A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.
Topics: Adenosine A2 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Comorbidity; Coronary Artery Disease; Double-Blind Method; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Placebo Effect; Prevalence; Purines; Pyrazoles; Radionuclide Imaging; Risk Assessment; Risk Factors; United States; Young Adult | 2012 |
9 other study(ies) available for regadenoson and Kidney Failure, Chronic
| Article | Year |
|---|---|
The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date.
Topics: Adult; Aged; Exercise Test; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Perfusion Imaging; Prognosis; Purines; Pyrazoles; Retrospective Studies; Tomography, Emission-Computed, Single-Photon | 2022 |
Regadenoson use for stress myocardial perfusion imaging in advance chronic kidney disease and dialysis: Safe, effective, and efficient.
Topics: Humans; Kidney Failure, Chronic; Myocardial Perfusion Imaging; Purines; Pyrazoles; Renal Dialysis | 2018 |
Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunction.
Topics: Adenosine A2 Receptor Agonists; Aged; Biomarkers; Cardiovascular Diseases; Electrocardiography; Endpoint Determination; Female; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Prognosis; Purines; Pyrazoles; Radiopharmaceuticals; Risk Factors; Survival Rate; Tomography, Emission-Computed, Single-Photon | 2014 |
Further evidence for the robustness of regadenoson stress myocardial perfusion SPECT: its predictive value for cardiac events in chronic renal failure.
Topics: Adenosine A2 Receptor Agonists; Cardiovascular Diseases; Female; Humans; Kidney Failure, Chronic; Male; Organophosphorus Compounds; Organotechnetium Compounds; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2014 |
The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.
Topics: Age Distribution; Cardio-Renal Syndrome; Chicago; Comorbidity; Coronary Artery Disease; Death, Sudden, Cardiac; Exercise Test; Female; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Perfusion Imaging; Prognosis; Purines; Pyrazoles; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Sex Distribution; Single-Blind Method; Survival Rate; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2017 |
Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: Does it matter?
Topics: Cardiovascular Diseases; Humans; Kidney Failure, Chronic; Myocardial Perfusion Imaging; Purines; Pyrazoles; Renal Insufficiency, Chronic; Risk Assessment; Tomography, Emission-Computed, Single-Photon | 2017 |
Safety of regadenoson in patients with end-stage renal disease.
Topics: Exercise Test; Female; Follow-Up Studies; Heart Diseases; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prognosis; Purines; Pyrazoles; Reproducibility of Results; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2010 |
Complete heart block associated with regadenoson: a real side effect.
Topics: Adenosine A2 Receptor Agonists; Aged; Aminophylline; Bronchodilator Agents; Female; Heart Block; Humans; Kidney Failure, Chronic; Kidney Transplantation; Myocardial Perfusion Imaging; Preoperative Period; Purines; Pyrazoles; Renal Dialysis; Treatment Outcome; Vasodilator Agents | 2012 |
Use of regadenoson in end-stage renal disease.
Topics: Diarrhea; Dizziness; Exercise Test; Female; Humans; Kidney Failure, Chronic; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2013 |